based on 4 analysts
50.00%
Buy
50.00%
Hold
0.00%
Sell
Based on 4 analysts offering long term price targets for Glaxosmithkline Pharmaceuticals Ltd. An average target of ₹2914.5
Source: S&P Global Market Intelligence
Glaxosmithkline Pharmaceuticals Ltd price forecast by 4 analysts
Upside of22.40%
High
₹3250
Target
₹2914.50
Low
₹2550
Glaxosmithkline Pharmaceuticals Ltd target price ₹2914.5, a slight upside of 22.4% compared to current price of ₹2343.15. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glaxosmithkline Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:18.09%
Forecast
Actual
Including amortisation and stock based compensations
Glaxosmithkline Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:66.24%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -9.45 % |
3 Month Return | -15.91 % |
1 Year Return | + 41.2 % |
Market Stats | |
Previous Close | ₹2,381.20 |
Open | ₹2,382.10 |
Volume | 74.34K |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹40,338.96Cr |
P/E Ratio | 51 |
PEG Ratio | 5.26 |
Market Cap | ₹40,338.96 Cr |
P/B Ratio | 18.45 |
EPS | 34.83 |
Dividend Yield | 1.65 |
Sector | Pharmaceuticals |
ROE | 36.83 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹40,338.96 Cr | 9.11% | 0.56 | ₹589 Cr | ₹3,453 Cr | |
BUY | ₹14,467.33 Cr | -1.94% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
BUY | ₹72,870.26 Cr | 35.81% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
HOLD | ₹98,409.68 Cr | 56.62% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
BUY | ₹61,710.00 Cr | 25.37% | 0.53 | NA | NA |
Organisation | Glaxosmithkline Pharmaceuticals Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Glaxosmithkline Pharmaceuticals Ltd
Glaxo Pharma Reports Strong Q2FY25 Performance - 15 Nov, 2024
GSK Celebrates 100 Years in India - 12 Nov, 2024
GSK Pharma Declares Special Interim Dividend - 04 Nov, 2024
GlaxoSmithKline Announces Special Interim Dividend - 03 Nov, 2024
GSK Pharma Reports Strong Q2 Earnings and Dividend - 30 Oct, 2024
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 2 quarters, 182.33 Cr → 252.5 Cr (in ₹), with an average increase of 27.8% per quarter
MF Holding Up
Mutual Funds have increased holdings from 4.71% to 4.98% in Sep 2024 quarter
FII Holding Up
Foreign Institutions have increased holdings from 4.02% to 4.36% in Sep 2024 quarter
Revenue Rich
Revenue is up for the last 2 quarters, 850.29 Cr → 1.05K Cr (in ₹), with an average increase of 19.0% per quarter
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 63.2% return, outperforming this stock by 22.0%
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 146.0% return, outperforming this stock by 112.2%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 75.00% of holdings in Sep 2024 quarter
Price Dip
In the last 7 days, GLAXO stock has moved down by -2.6%
Retail Holding Down
Retail Investor have decreased holdings from 13.48% to 13.30% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 75% | 0.00 | |
Foreign Institutions | 4.36% | 8.59 | |
Mutual Funds | 4.98% | 5.75 | |
Retail Investors | 13.3% | ||
Others | 2.36% |
Glaxosmithkline Pharmaceuticals Ltd in the last 5 years
Lowest (-81.64x)
December 28, 2020
Today (51.00x)
December 5, 2024
Industry (57.40x)
December 5, 2024
Highest (333.07x)
September 15, 2020
Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 16.09% since last year same period to ₹252.50Cr in the Q2 2024-2025. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated 38.49% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending September 2024, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹12 - translating a dividend yield of 1.85%.
Read More about DividendsBearish
Neutral
Bullish
Glaxosmithkline Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) share price today is ₹2343.15
Glaxosmithkline Pharmaceuticals Ltd is listed on NSE
Glaxosmithkline Pharmaceuticals Ltd is listed on BSE
PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 51
PE ratio = Glaxosmithkline Pharmaceuticals Ltd Market price per share / Glaxosmithkline Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is 74.34K.
Today’s market capitalisation of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is ₹40338.96Cr.
Glaxosmithkline Pharmaceuticals Ltd(GLAXO | Price |
---|---|
52 Week High | ₹3088 |
52 Week Low | ₹1661.35 |
Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2343.15. It is down -24.12% from its 52 Week High price of ₹3088
Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2343.15. It is up 41.04% from its 52 Week Low price of ₹1661.35
Glaxosmithkline Pharmaceuticals Ltd(GLAXO | Returns |
---|---|
1 Day Returns | -38.05% |
1 Month Returns | -9.45% |
3 Month Returns | -15.91% |
1 Year Returns | 41.2% |